The Effect of Peer-Guided Education on Organ Donation on Organ Donation Attitude

June 18, 2026 updated by: Gülsüm ÖZCAN ÇETİNER, Suleyman Demirel University
This research will be conducted to determine the effect of peer-guided organ donation education given to anesthesia students on their attitudes towards organ donation.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

There are many people waiting for organ donation in our country. Therefore, it is important to develop a positive attitude towards organ donation in our society. This study was planned to determine the effect of peer-guided organ donation education to be given to anesthesia students on the attitude towards organ donation. In the study, anesthesia students will be informed about organ donation. It was thought that the education given towards organ donation will develop a positive attitude in students.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
46

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Isparta
      • Isparta, Isparta, Turkey (Türkiye), 32200
        • Suleyman Demirel University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Being 17 years of age or older, studying in the program in which the research is conducted, and agreeing to participate in the research voluntarily.

Exclusion Criteria:

  • Having received prior training on organ donation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Educational intervention
The educational intervention consists of a two-hour program prepared by the peer student in line with the literature. The training session was planned to be completed in four sessions, with 30 minutes of session time. These four sessions cover the traditional education model with the help of slide presentation. The content of the training model was planned to use techniques such as participant activity, group work and discussion, and a brochure prepared by the researcher.
Behavioral: Peer-led education on organ donation
The training on organ donation will be conducted under peer guidance. The training will be implemented using face-to-face lectures, slide presentations, brochures and group discussions. It will be conducted at Süleyman Demirel University in the 2025-2026 academic year for first-year anesthesia students. The content of the training includes the concept of organ donation, the conditions for becoming a donor (physical, legal, religious), the social dimension of organ donation and attitude development sessions through group discussions. The training, planned in four sessions, will last two hours in total.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in "Organ Donation Attitude Scale" Positive Attitude Sub-dimension Score
Time Frame: Baseline, immediately after completion of the 4-week training program (Week 4), and 1 month after completion of the training program (Week 8).
The Organ Donation Attitude Scale was originally developed by Parisi and Kanz (1986) and later adapted to 46 items by Kent and Owens (1995). The Turkish validity and reliability study was conducted by Yazıcı Sayın (2016). After removing items 6, 7, 12, 19, 27, and 45, the final version consists of 40 items rated on a 6-point Likert scale (from "strongly agree" to "strongly disagree") and includes two subscales. TThe Positive Attitude Subscale of the Organ Donation Attitude Scale consists of 20 items assessing altruism and moral values and beliefs related to organ donation. Each item is rated on a 6-point Likert scale. The total subscale score ranges from 20 to 120. Higher scores indicate a more positive attitude toward organ donation and therefore represent a better outcome. Change in scores will be evaluated across the three assessment time points.
Baseline, immediately after completion of the 4-week training program (Week 4), and 1 month after completion of the training program (Week 8).
Change in "Organ Donation Attitude Scale" Negative Attitude Sub-dimension Score
Time Frame: Baseline, immediately after completion of the 4-week training program (Week 4), and 1 month after completion of the training program (Week 8).
The Organ Donation Attitude Scale was originally developed by Parisi and Kanz (1986) and later adapted to 46 items by Kent and Owens (1995). The Turkish validity and reliability study was conducted by Yazıcı Sayın (2016). After removing items 6, 7, 12, 19, 27, and 45, the final version consists of 40 items rated on a 6-point Likert scale (from "strongly agree" to "strongly disagree") and includes two subscales. The Negative Attitude Subscale of the Organ Donation Attitude Scale consists of 20 items assessing fear of medical neglect and fear of bodily injury related to organ donation. Each item is rated on a 6-point Likert scale. The total score ranges from 20 to 120. Higher scores indicate a more negative attitude toward organ donation and represent a worse outcome. Changes in the Negative Attitude Subscale score will be evaluated at baseline, immediately after the training program, and at the 1-month follow-up.
Baseline, immediately after completion of the 4-week training program (Week 4), and 1 month after completion of the training program (Week 8).

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in organ/tissue donation knowledge, awareness, and donation intention item scores
Time Frame: Baseline, immediately after completion of the 4-week training program (Week 4), and 1 month after completion of the training program (Week 8).
Participants' knowledge, awareness, and intention regarding organ/tissue donation were assessed using items included in the researcher-developed organ/tissue donation knowledge and attitude form. These items evaluated participants' perceived level of knowledge about organ/tissue donation, knowledge of the required steps to become an organ/tissue donor, intention to donate organs/tissues, and perceived access to reliable sources of information about organ donation. Each item was scored using Likert-type response options. Higher scores indicated a more positive level of knowledge, awareness, or donation intention for the relevant item. Changes in item scores were evaluated across the pre-test, post-test, and follow-up measurements.
Baseline, immediately after completion of the 4-week training program (Week 4), and 1 month after completion of the training program (Week 8).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Suleyman Demirel University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Gulsum OZCAN CETINER, Lecturer, Suleyman Demirel University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 20, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 11, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 25, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 3, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 18, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 23, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 23, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 18, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2025/95 (MTÜ Health Sciences Ethics Committee)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings